Literature DB >> 10160477

Clinical and cost considerations in the pharmacotherapy of vulvovaginal candidiasis.

I W Fong1.   

Abstract

Vulvovaginal candidiasis (VVC) is a frequent cause of morbidity in women of reproductive age. Most women will experience 1 or 2 episodes in their lifetime, but a smaller population develop chronic recurrent disease. There are few data on cost or pharmacoeconomic considerations in the management of this condition. The disease does not usually result in long term disability, loss of employment or death, but could affect a woman's work performance through irritability, frustration and unhappiness. This review attempts to estimate the least costly programme or regimen (as the efficacy of different regimens is similar) that would be applicable to patients, third-party payers and society. Nonprescription or over-the-counter (OTC) antifungal preparations could have an impact on overall cost in the management of VVC. In the management of infrequent acute VVC, an OTC preparation would be least costly to the healthcare system (provided that the diagnosis was correct). The strategies used to control symptoms in patients with chronic recurrent VVC should be based on the frequency of recurrent episodes. For patients with less than 12 episodes a year, empirical self-treatment at the onset of symptoms with an OTC agent (e.g. intravaginal clotrimazole 500mg) is less costly and preferable to patients than monthly prophylaxis. Patients with a greater frequency of recurrences may benefit from monthly, daily or twice weekly prophylaxis. At present, for very frequent recurrences, intravaginal clotrimazole 200mg twice weekly appears to be as effective as daily oral ketoconazole, and may be safer and less costly. However, because of the lack of prospective controlled studies, most of these recommendations are based on hypothetical reasonings. Furthermore, the disadvantages of OTC antifungals include the potential for overuse and inappropriate use, possibly resulting in the delayed diagnosis and treatment of other conditions. On balance, OTC preparations may provide patients with faster and more economical care, and improve healthcare delivery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10160477     DOI: 10.2165/00019053-199609060-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  35 in total

1.  Anaphylactic reaction after oral fluconazole.

Authors:  G Neuhaus; N Pavic; M Pletscher
Journal:  BMJ       Date:  1991-06-01

2.  Topical drugs for vaginal candidiasis.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1991-08-23       Impact factor: 1.909

3.  Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment.

Authors:  F Davidson; R F Mould
Journal:  Br J Vener Dis       Date:  1978-06

4.  Nystatin vaginal cream in monilial vaginitis.

Authors:  J H Isaacs
Journal:  IMJ Ill Med J       Date:  1973-03

Review 5.  Candidal vulvovaginitis.

Authors:  J D Sobel
Journal:  Clin Obstet Gynecol       Date:  1993-03       Impact factor: 2.190

6.  Adult vaginitis.

Authors:  F J Fleury
Journal:  Clin Obstet Gynecol       Date:  1981-06       Impact factor: 2.190

7.  Recurrent Candida infection.

Authors:  R Hurley
Journal:  Clin Obstet Gynaecol       Date:  1981-04

8.  Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy.

Authors:  J D Sobel
Journal:  N Engl J Med       Date:  1986-12-04       Impact factor: 91.245

9.  Terconazole and miconazole cream for treating vulvovaginal candidiasis. A comparison.

Authors:  S L Corson; R R Kapikian; R Nehring
Journal:  J Reprod Med       Date:  1991-08       Impact factor: 0.142

10.  Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis.

Authors:  E Hilton; H D Isenberg; P Alperstein; K France; M T Borenstein
Journal:  Ann Intern Med       Date:  1992-03-01       Impact factor: 25.391

View more
  2 in total

1.  Serious fungal infections in Canada.

Authors:  S F Dufresne; D C Cole; D W Denning; D C Sheppard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-04       Impact factor: 3.267

2.  The synthetic melanocortin (CKPV)2 exerts anti-fungal and anti-inflammatory effects against Candida albicans vaginitis via inducing macrophage M2 polarization.

Authors:  Hai-xia Ji; Yu-lian Zou; Jing-jing Duan; Zhi-rong Jia; Xian-jing Li; Zhuo Wang; Li Li; Yong-wen Li; Gen-yan Liu; Ming-qing Tong; Xiao-yi Li; Guo-hui Zhang; Xiang-rong Dai; Ling He; Zhi-yu Li; Cong Cao; Yong Yang
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.